Psomagen, Inc. Share Price

Equities

A950200

KR8840150005

Biotechnology & Medical Research

End-of-day quote Korea S.E. 23:00:00 15/05/2024 BST 5-day change 1st Jan Change
4,850 KRW +0.73% Intraday chart for Psomagen, Inc. +0.10% -4.90%

Financials

Sales 2022 43.37B 31.97M 2.53B Sales 2023 32.27B 23.79M 1.88B Capitalization 98.1B 72.3M 5.72B
Net income 2022 -1.05B -772K -61.07M Net income 2023 -4.29B -3.16M -250M EV / Sales 2022 3.21 x
Net cash position 2022 9.71B 7.15M 566M Net cash position 2023 6.03B 4.44M 351M EV / Sales 2023 2.85 x
P/E ratio 2022
-142 x
P/E ratio 2023
-22.9 x
Employees 88
Yield 2022 *
-
Yield 2023
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.73%
1 week+0.10%
Current month-0.72%
1 month+3.85%
3 months-3.19%
6 months-5.09%
Current year-4.90%
More quotes
1 week
4 650.00
Extreme 4650
4 935.00
1 month
4 630.00
Extreme 4630
5 050.00
Current year
4 550.00
Extreme 4550
6 340.00
1 year
4 550.00
Extreme 4550
7 880.00
3 years
4 550.00
Extreme 4550
17 000.00
5 years
4 550.00
Extreme 4550
27 500.00
10 years
4 550.00
Extreme 4550
27 500.00
More quotes
Managers TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - -
More insiders
Date Price Change Volume
16/05/24 4,850 +0.73% 22,836
14/05/24 4,815 +2.23% 17,161
13/05/24 4,710 -1.88% 23,333
10/05/24 4,800 -0.93% 22,041
09/05/24 4,845 +0.10% 11,007

End-of-day quote Korea S.E., May 15, 2024

More quotes
Psomagen, Inc. is an integrative omics solutions and contract laboratory services provider. The Company’s labs are United States-based and are Clinical Laboratory Improvement Amendments (CLIA) certified and include certified authorization professional (CAP) accredited facilities. Its omics services include Whole-Genome Sequencing, Whole-Exome Sequencing, Targeted Sequencing, Sanger Sequencing, Microarray Analysis, Epigenomics Sequencing, Metagenomics Sequencing, Ribonucleic acid (RNA) Sequencing, Single-Cell Sequencing and Biomarker Profiling. It also offers SARS-CoV-2 Variant Sequencing services. The Company’s Microarray Analysis is a multiplex genomics approach that targets and quantifies specific genes by hybridizing the nucleic acid to a chip and providing an output of genotyping data on a genome-wide scale. Epigenomics is the study of epigenetic changes, such as chromatin assembly, histone modification, and Deoxyribonucleic acid DNA-protein interaction in a cell.
More about the company
  1. Stock Market
  2. Equities
  3. A950200 Stock